Pharma forum ends, now industry wants action
This article was originally published in Scrip
Executive Summary
EU member states should give pharmaceutical companies clear guidance on the evidence that will be needed to secure an appropriate reward for innovative drugs. Industry should have a role in providing drug information to patients. And the authorities should adhere to a set of good practices in assessing relative effectiveness.